# Angiotensin II Receptor Blockers (ARBs)

## Examples

- `losartan`
- `valsartan`
- `irbesartan`
- `candesartan`
- `olmesartan`
- `telmisartan`
- `eprosartan`

## Mechanism of Action (MOA)

- Competitively **block angiotensin II (AII)** binding to **AT₁ receptors** on vascular smooth muscle and adrenal cortex.
- This results in:
  - ↓ **Vasoconstriction** → ↓ afterload
  - ↓ **Aldosterone secretion** → ↓ Na⁺ & water retention
  - ↓ **Sympathetic activation**

- **Bradykinin metabolism is unaffected**, unlike ACE inhibitors.
- **Net effect:** ↓ BP, ↓ preload & afterload, ↓ cardiac remodeling.

## Pharmacodynamics

| Action             | Effect                                                            |
| :----------------- | :---------------------------------------------------------------- |
| **Vasculature**    | Arteriolar & venous dilation → ↓ BP                               |
| **Adrenal cortex** | ↓ Aldosterone → ↓ Na⁺, ↓ water retention                          |
| **Cardiac**        | ↓ Afterload, ↓ ventricular remodeling                             |
| **Renal**          | ↓ intraglomerular pressure → slows nephropathy (esp. in diabetes) |

## Pharmacokinetics

| Drug          | Bioavailability |           Half-life           | Notes                       |
| :------------ | :-------------: | :---------------------------: | :-------------------------- |
| `losartan`    |      ~33%       | 2 h (active metabolite 6–9 h) | Prodrug; hepatic activation |
| `valsartan`   |      ~25%       |             6–9 h             | Not a prodrug               |
| `candesartan` |       Low       |    9 h (active form 32 h)     | Prodrug                     |
| `telmisartan` |      ~50%       |             ~24 h             | Longest-acting; once daily  |
| `irbesartan`  |      ~60%       |            11–15 h            | High bioavailability        |

- **Absorption:** oral, variable with food.
- **Metabolism:** hepatic (CYP2C9 or CYP3A4).
- **Excretion:** renal + biliary.

## Indications

- **Primary hypertension**
- **Heart failure (HFrEF)**
- **Post–myocardial infarction**
- **Diabetic nephropathy / CKD with proteinuria**
- **ACE inhibitor intolerance** (esp. due to cough or angioedema)

## Adverse Effects

| System               | Effect                              | Notes                      |
| :------------------- | :---------------------------------- | :------------------------- |
| **CVS**              | Hypotension (first dose), dizziness | esp. if volume-depleted    |
| **Renal**            | ↑ Creatinine, **hyperkalemia**      | ↓ aldosterone              |
| **Others**           | Fatigue, headache                   | Mild                       |
| **Hypersensitivity** | **Angioedema** (rare)               | Less common than ACEIs     |
| **Respiratory**      | **No cough**                        | Major advantage over ACEIs |

## Cautions

- **Renal impairment:** monitor K⁺, Cr.
- **Hypovolemia:** risk of hypotension.
- **Avoid dual blockade** (ACEI + ARB) — no added benefit, ↑ adverse effects.

## Contraindications

- **Pregnancy** (fetotoxic)
- **Bilateral renal artery stenosis**
- **Severe hyperkalemia**
- **History of angioedema (with ARB itself)**

## Drug Interactions

- Additive hyperkalemia with **K⁺-sparing diuretics**, supplements, or **NSAIDs**.
- NSAIDs may blunt antihypertensive effect.
- Avoid combining with **ACEIs** or **Aliskiren** in diabetics.

## Key Point Summary

| Feature                  | ARBs                                               |
| :----------------------- | :------------------------------------------------- |
| **Target**               | Block Angiotensin II at AT₁ receptor               |
| **Effect on Bradykinin** | None → **No cough**                                |
| **BP Effect**            | ↓ SVR, ↓ aldosterone                               |
| **Renal Effect**         | ↓ proteinuria; monitor K⁺                          |
| **Adverse Effects**      | Hypotension, hyperkalemia, rare angioedema         |
| **Contraindications**    | Pregnancy, bilateral renal artery stenosis         |
| **Best Use**             | When ACEIs not tolerated (e.g., cough, angioedema) |

## ACE Inhibitors vs ARBs — Comparison Table

| Feature              | ACE Inhibitors                    | ARBs                   |
| :------------------- | :-------------------------------- | :--------------------- |
| **Mechanism**        | ↓ Ang II formation (ACE blockade) | Block AT₁ receptors    |
| **Bradykinin**       | ↑ (causes cough, angioedema)      | Unaffected             |
| **Cough**            | Common                            | Rare                   |
| **Angioedema**       | More frequent                     | Rare                   |
| **Renal Protection** | Yes                               | Yes (similar efficacy) |
| **Pregnancy**        | Contraindicated                   | Contraindicated        |
| **Best For**         | First-line in hypertension, CHF   | ACEI intolerance cases |
